Specific correlations between IL-4 and MIP-1 beta, IL-4 and IFN-gamma, IL-5 and IL-12p70, and IL-5 and IFN-gamma in PCa patients did not occur in healthy individuals, which might guide future drug targets and candidates with the potential to predict FDA-approved prostate cancer treatment responses by targeting cytokine levels and the oncogenesis pathways. The gene discussed is IFNG; the disease is prostate carcinoma.